Apollo Hospitals Group, India’s premier healthcare provider, has unveiled the ZAP-X Gyroscopic Radio surgery Platform, marking a significant milestone as the first in South Asia to introduce this revolutionary technology. This ground-breaking advancement in brain tumor treatment is poised to redefine patient care, offering non-invasive, pain-free sessions lasting just 30 minutes. With ZAP-X, Apollo Hospitals continues its legacy of innovation and commitment to providing world-class healthcare solutions for patients in India and beyond.
ZAP-X heralds a new era in brain tumor treatment, prioritizing patient comfort and recovery. Its non-invasive nature and shorter treatment duration not only minimize patient discomfort but also accelerate recovery times. By utilizing a self-shielded, gyroscopic linear accelerator design, ZAP-X ensures precise targeting of tumor cells while minimizing radiation exposure to surrounding healthy brain tissue. This innovative approach significantly enhances patient outcomes by avoiding critical structures like the brain stem, eyes, and optic nerves, thus safeguarding cognitive function.
The clinical capabilities of ZAP-X extend beyond brain tumors to include the treatment of various neurological conditions such as Arteriovenous Malformations (AVMs), Trigeminal Neuralgias, Movement Disorders like Parkinson’s disease, Epilepsy, and other intracranial lesions. Dr. Prathap Chandra Reddy, Founder Chairman of Apollo Hospitals Group, emphasized the significance of ZAP-X, stating that it enables non-invasive, pain-free sessions with minimal radiation exposure. Advanced safety protocols, including instant error detection and reduced radiation leakage, ensure the well-being and quality of life of patients post-treatment.
ZAP-X’s key advantages include its non-invasiveness, pain-free sessions, frameless design, pinpoint accuracy, and real-time image guidance. With high success rates, including over 95% control rate in 10 years for various conditions and an exceptional 99.4% control rate in 5 years for small, defined tumors, ZAP-X demonstrates its effectiveness in providing relief with minimal side effects.
Prof. John R. Adler, Founder and CEO of Zap Surgical and Professor of Neurosurgery at Stanford School of Medicine, hailed ZAP-X as a significant medical advancement. He emphasized that eligible patients no longer need to undergo debilitating surgical resections or whole-brain radiotherapy, as ZAP-X offers quick treatment in an outpatient setting, allowing patients to return to normal activities the same day with no incisions and no pain.
Traditionally, brain surgeries last 3-4 hours, requiring extended hospitalization and anesthesia. In contrast, ZAP-X completes treatment within a single 30-minute session, enabling a day-care procedure and allowing patients to return home post-treatment without the need for prolonged hospital stays.
The Apollo Institute of Neurosciences stands as a pioneering force in revolutionizing neurological care across India and the region. With over 180,000 successful neurosurgeries and a formidable team of over 300 neurosurgeons and neurologists, Apollo Hospitals treats more than 25,000 patients annually, performing nearly 6,000 brain and spinal surgeries. Leveraging cutting-edge AI technology, the Institute has redefined stroke protocols, ensuring swifter and more accurate diagnosis and treatment.
Apollo Hospitals, founded in 1983, has evolved into the world’s largest integrated healthcare platform, with over 10,000 beds across 71 hospitals, nearly 6,000 pharmacies, and over 200 clinics and diagnostic centers, along with 150 telemedicine centers. With a commitment to research and innovation, Apollo continues to invest in bringing the most cutting-edge technologies, equipment, and treatment protocols to ensure patients receive the best available care in the world.
In conclusion, the unveiling of the ZAP-X platform by Apollo Hospitals represents a monumental leap forward in brain tumor care, offering patients a non-invasive, pain-free treatment option with minimal side effects and faster recovery times. This innovation underscores Apollo’s dedication to transforming lives and reaffirms its position as a global leader in healthcare excellence.
